Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases
Journal of Cancer Research and Clinical Oncology · 2023
DOI: 10.1007/s00432-023-04582-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Antonio Pizuorno Machado und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Autoimmune Diseases, Neoplasms, Symptom Flare Up. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
PURPOSE: Immune checkpoint inhibitor (ICI) therapy can predispose patients to immune-related adverse events (irAEs) and autoimmune disease (AD) flare-ups, but the characteristics of irAEs among patients with pre-existing ADs are largely unknown. We conducted this study to determine the clinical courses, irAEs, AD flares, treatment, and outcomes of patients with AD on ICIs. METHODS: This was a retrospective study of adult cancer patients at a large cancer center who were diagnosed with ADs before undergoing ICI therapy. Patients' clinical courses, complications, treatments, and outcomes related to both ADs flares and irAEs were collected and analyzed. RESULTS: The study included 197 patients. Most (55.4%) were women. Melanoma comprised the highest proportion (28.4%) of malignancies, and most (83.8%) patients received PD-1/PD-L1 inhibitors. Fifty (25.3%) patients developed a new irAE after starting ICI therapy, while 29 (14.7%) patients had an AD flare-up. Patients with inflammatory bowel disease had the highest incidence of AD flare-ups (31.7%), while patients with Hashimoto hypothyroidism had the highest incidence of new irAEs (39.2%). Patients with inflammatory bowel disease had more severe adverse events. In our cohort, patients with a new diagnosis of irAE were treated with immunosuppressive therapy. AD flares were managed similarly. With regard to irAE manifestations, the most common presentations were colitis (24 [12.1%] patients), hepatic transaminase elevations (8 [4%] patients), and pneumonitis (7 [3.5%] patients). CONCLUSION: Our findings suggest that patients with gastrointestinal and rheumatologic ADs had a higher incidence of AD flare-ups, while patients with Hashimoto hypothyroidism and neurologic ADs had a higher incidence of new irAEs. Patients with prior ADs experiencing flare-ups or new irAEs after ICI therapy tend to require aggressive immunosuppressive treatment. Thorough evaluation of baseline disease status, appropriate medical management before ICI therapy, and early recognition of inflammatory exacerbation may help ensure long-term success in treating and improving outcomes in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
- Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
- Department of Internal Medicine, Baylor College of Medicine, Houston, TX, 77030, USA.
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
- Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. ywang59@mdanderson.org.
Zitieren
APA
Pizuorno Machado, A., Shatila, M., Liu, C., Wang, J., Altan, M., Zhang, H. C., Thomas, A., & Wang, Y. (2023). Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04582-9
Vancouver
Pizuorno Machado A, Shatila M, Liu C, Wang J, Altan M, Zhang HC, et al. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-023-04582-9
BibTeX
@article{PizuornoMachado2023,
author = {Pizuorno Machado, Antonio and Shatila, Malek and Liu, Cynthia and Wang, Jianbo and Altan, Mehmet and Zhang, Hao Chi and Thomas, Anusha and Wang, Yinghong},
title = {Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2023},
doi = {10.1007/s00432-023-04582-9}
}
EUVIMED